351 million yuan invested in products such as the new crown vaccine of Sri Lanka, and the market value of Tibet's pharmaceutical industry exceeded 15 billion!

Guide: Tibet's pharmaceutical industry has been up and down for many days, rising 178% this year
affected by the news of investment in a new crown vaccine, today (June 16), the Tibetan pharmaceutical industry rose and stopped, reported a new high of 61.49 yuan, temporarily traded 645 million yuan, the latest total market value of 15.246 billion yuanIt is worth noting that the share price of KangZhe Pharmaceuticals, a major shareholder in Tibet's pharmaceutical industry, has also increasedSource: Sina Financeanother new crown vaccine concept unit? On the evening of June 15,, Tibet Pharmaceuticals announced that it had developed research and development in cooperation with SpMicrobes and had granted the world's exclusive rights to the development, registration, production, use and commercialization of the vaccine, including the new crown vaccine, tuberculosis vaccine and influenza vaccineTibet Pharmaceuticals has invested 351 million yuan in micro-organisms in stages in accordance with the progress of research and development of the new crown vaccine, tuberculosis vaccine and influenza vaccine, and has obtained the exclusive global license for the vaccineAccording to the requirements, for the new crown vaccine, the Tibetan pharmaceutical industry will pay an advance payment of 35 million yuan (including total tax) to the micro-organisms, and for the TB vaccine and influenza vaccine, the Tibetan pharmaceutical industry will pay a deposit price of 500,000 yuan (totalling 1 million yuan) to the micro-organisms, according to which the micro-organisms will be locked in the exclusive authorization of the products in the global region under this strategic cooperationJanuary 2020, the micro-organisms launched the new crown mRNA vaccine research and development project, in cooperation with the China Center for Disease Control and Prevention and Tongji University affiliated Oriental HospitalAt present, the pharmaconographic studies of all candidate vaccines have been completed and clinical trials are expected to be conducted in the near futureFor TB vaccines and influenza vaccines, preliminary inviviable tests in animals have been completed, followed by formal toxicology and pharmaorological evaluationspecifically, the market value of the Tibetan pharmaceutical industry has risen by more than a billion because of the good newsHowever, the heat of the new crown outbreak is also at risk, on March 1st the Shanghai-Shenzhen Stock Exchange launched a criticism and punishment of the three companies of Zhongda, Borui Pharmaceuticals and Hainan Hai Medicine in the hot spot of The Strong Red Siweiin this foreign investment announcement, the Tibetan pharmaceutical industry also made a special warning of the related risks, the Tibetan pharmaceutical industry said that the cooperation with the micro-organisms, only to obtain the relevant vaccine's global exclusive development, production, use and commercial rights, the company will not become the rights of the relevant vaccine ownersThe product is still in the preclinical research stage in China, and overseas related work has not yet started In addition, , due to the generally long time to market of vaccines, preclinical research, clinical trials are at risk of failure, and the availability of clinical trial approval, listing approval, certification/verification through production facilities (if applicable), and the time required for approval, and so on Kangzhe Pharmaceuticals has risen Tibet Pharmaceuticals has risen 178% this year
Public information shows that in 2012, Kangzhe Pharmaceuticals, a wholly-owned subsidiary of Kangzhe Pharmaceuticals, and its co-operatives, took a stake in Tibet Pharmaceuticals, accounting for 3.72% of the total share capital of Tibet Pharmaceuticals, becoming its fourth largest shareholder Analysts have pointed out that Kangzhe Pharmaceuticals' move is aimed at further securing future product rights for the new living product, since Kangzhe Pharmaceuticals has been granted exclusive agency rights to the product since 2008 2014 Tibet Pharmaceuticals announced that Kangzhe Pharmaceuticals will be granted a portion of the company's second shareholder, Xinphoenix, as well as a full stake in The Tibet Tongying and its co-operator, Tianjin Tongsheng Upon completion of the transaction, Kangzhe Pharmaceuticals will hold a stake of 26.61 percent, surpassing Huaxi Pharmaceuticals as its largest shareholder the news, the shares of KangZhe Pharmaceuticals, a major shareholder in Tibet's pharmaceutical industry, also rose As of 4 p.m., Kangzhe Pharmaceuticals was up 7.04 percent at HK$9.430, with a turnover of HK$67.7753 million according to media reports , in December 2019, Tibet Pharmaceuticals shares reached a stage low of 20.71, and then climbed slowly, on May 22 this year, closed at 25.92 yuan, May 25 suddenly began a surge in the stock price, in less than a month, has risen 137 percent, and the stock has risen 178 percent so far this year Tibet Pharmaceuticals' 2019 financial results showed revenue of RMB1,256 million, up 22.20% YoY; the company said the better results were mainly due to a nearly 50 per cent year-on-year increase in sales of new live products Last year, the company's sales contributed 800 million yuan, with sales up 47.7 percent year-on-year, and gross margin was much higher than the rest of the products In the first quarter of this year, the company's net profit was 129 million yuan, up 81% note, the new life in 2017 for the first time into the health care catalog, in November 2019 successfully entered the new version of the health care catalog Against the backdrop of a 23.9 per cent price reduction, volumes are still ongoing and recently announced a 70 million yuan investment in Beijing Amet in exchange for a 9.86 percent stake in the target company, as well as the target company's four exclusive development rights in the Chinese market for research projects Analysts point out that the company intends to lay out the cardiovascular equipment field in order to complement the product line and enrich the source of performance responsible editor: penicillin this article is the drug intelligence network reprinted content, pictures, text copyright belongs to the original author, reprinted is intended to convey more information, does not represent the platform's views If you are involved in the content, copyright and other issues of the work, please contact this website message, we will delete the content in the first place Related: 's Tibetan , Tibetan pharmaceutical 00
00